| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
82,823,000 |
| Market
Cap: |
1.76(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$18.92 - $29.92 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 484 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Veracyte is a genomic diagnostics company. Co. develops tests that address clinical needs in the diagnosis, prognosis and treatment of cancer and other diseases. Co. provides tests in: thyroid cancer via its Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas; prostate cancer via its Decipher Biopsy and Radical Prostatectomy Genomic Classifiers; breast cancer via its Prosigna Breast Cancer Assay; lung cancer via its Percepta GSC and Percepta Nasal Swab Test; interstitial lung diseases including idiopathic pulmonary fibrosis via its Envisia Genomic Classifier; bladder cancer via its Decipher Bladder Genomic Classifier; and colon cancer via its Immunoscore Colon Cancer Test.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
11,539 |
21,539 |
104,169 |
521,685 |
| Total Sell Value |
$248,847 |
$492,446 |
$2,960,641 |
$13,780,081 |
| Total People Sold |
2 |
3 |
4 |
7 |
| Total Sell Transactions |
2 |
3 |
12 |
30 |
| End Date |
2024-03-14 |
2023-12-12 |
2023-06-13 |
2022-06-13 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-05-10 |
4 |
OE |
$2.68 |
$21,440 |
D/D |
8,000 |
103,292 |
|
- |
|
| Hall Christopher M |
President and COO |
• – – |
2019-05-06 |
4 |
AS |
$24.72 |
$2,904,715 |
D/D |
(115,000) |
28,714 |
|
- |
|
| Hall Christopher M |
President and COO |
• – – |
2019-05-06 |
4 |
OE |
$5.98 |
$840,775 |
D/D |
115,000 |
143,714 |
|
- |
|
| Hall Christopher M |
President and COO |
• – – |
2019-04-11 |
4 |
AS |
$25.09 |
$2,009,684 |
D/D |
(80,000) |
28,714 |
|
- |
|
| Hall Christopher M |
President and COO |
• – – |
2019-04-11 |
4 |
OE |
$2.68 |
$334,067 |
D/D |
80,000 |
108,714 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-04-10 |
4 |
AS |
$25.39 |
$203,084 |
D/D |
(8,000) |
95,292 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-04-10 |
4 |
OE |
$2.68 |
$21,440 |
D/D |
8,000 |
103,292 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-03-13 |
4 |
GD |
$0.00 |
$0 |
D/D |
7,300 |
95,292 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-03-11 |
4 |
AS |
$19.97 |
$159,746 |
D/D |
(8,000) |
102,592 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-03-11 |
4 |
OE |
$2.68 |
$21,440 |
D/D |
8,000 |
110,592 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2019-03-04 |
4 |
S |
$20.24 |
$356,709 |
D/D |
(17,625) |
48,624 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2019-03-04 |
4 |
OE |
$5.98 |
$105,398 |
D/D |
17,625 |
66,249 |
|
- |
|
| Treu Jesse I |
Director |
– • – |
2019-03-04 |
4 |
S |
$20.21 |
$8,632,722 |
I/I |
(427,151) |
0 |
|
- |
|
| Hall Christopher M |
President and COO |
• – – |
2019-03-03 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,282) |
28,714 |
|
- |
|
| Kennedy Keith |
Chief Financial Officer |
• – – |
2019-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,053) |
71,550 |
|
- |
|
| Anderson Bonnie H |
Chairman and CEO |
• • – |
2019-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(3,949) |
102,592 |
|
- |
|
| Hall Christopher M |
President and COO |
• – – |
2019-03-02 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,459) |
30,996 |
|
- |
|
| Treu Jesse I |
Director |
– • – |
2019-03-01 |
4 |
S |
$20.45 |
$5,623,750 |
I/I |
(275,000) |
12,193 |
|
- |
|
| Kennedy Keith |
Chief Financial Officer |
• – – |
2019-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
72,603 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2019-02-28 |
4 |
D |
$0.00 |
$0 |
D/D |
(813) |
48,587 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2019-02-28 |
4 |
S |
$20.42 |
$764,204 |
D/D |
(37,375) |
49,400 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2019-02-28 |
4 |
OE |
$5.43 |
$298,755 |
D/D |
37,375 |
86,775 |
|
- |
|
| Kennedy Giulia C |
Chief Scientific & Med Officer |
• – – |
2019-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
40,000 |
49,400 |
|
- |
|
| Jones Evan/ Fa |
Director |
– • – |
2019-02-28 |
4 |
S |
$20.37 |
$1,527,803 |
I/I |
(75,000) |
204,653 |
|
- |
|
| Treu Jesse I |
Director |
– • – |
2019-02-28 |
4 |
S |
$20.44 |
$7,176,400 |
I/I |
(350,000) |
14,216 |
|
- |
|
524 Records found
|
|
Page 16 of 21 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.41 (1.96%) 
